Strong ESMO Data Fail to Lift Tango Therapeutics as Investors Sell the News
Updated Phase 1/2 data at ESMO showed 82% ORR and 88% 9-month PFS with vopimetostat plus daraxonrasib in previously treated MTAP-deleted RAS-mutant PDAC.
Updated Phase 1/2 data at ESMO showed 82% ORR and 88% 9-month PFS with vopimetostat plus daraxonrasib in previously treated MTAP-deleted RAS-mutant PDAC.
Strong 92% ORR and 90% 6-month PFS in pancreatic cancer combo data fuel bullish sentiment.
Jefferies turned bullish on Tango Therapeutics as early cancer data and big market potential lifted its price target.
Tango drug combo shows 92% response in advanced pancreatic cancer, with strong early results and good safety in trials.
Mizuho starts coverage on Tango Therapeutics with an Outperform rating and $19 price target, highlighting strong potential for lead drug vopimetostat in tough cancers like pancreatic and lung.
Stifel initiates coverage of Tango Therapeutics with a Buy rating and $15 target, citing strong potential for its PRMT5 inhibitor vopimetostat and forecasting $1.2B in peak global revenue by 2035.